
The following have been reloaded with a version change:
  1) GCCcore/8.3.0 => GCCcore/9.3.0
  2) binutils/2.32-GCCcore-8.3.0 => binutils/2.34-GCCcore-9.3.0
  3) zlib/1.2.11-GCCcore-8.3.0 => zlib/1.2.11-GCCcore-9.3.0

2021-02-04 18:40:28 | INFO | fairseq_cli.train | Namespace(activation_dropout=0.0, activation_fn='relu', adam_betas='(0.9, 0.98)', adam_eps=1e-08, adaptive_input=False, adaptive_softmax_cutoff=None, adaptive_softmax_dropout=0, all_gather_list_size=16384, arch='transformer_vaswani_wmt_en_de_big', attention_dropout=0.0, best_checkpoint_metric='bleu', bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', clip_norm=0.0, cpu=False, criterion='label_smoothed_cross_entropy', cross_self_attention=False, curriculum=0, data='../../../data-bin/phrase4_0.5_tag_rare_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoder_attention_heads=16, decoder_embed_dim=1024, decoder_embed_path=None, decoder_ffn_embed_dim=4096, decoder_input_dim=1024, decoder_layerdrop=0, decoder_layers=6, decoder_layers_to_keep=None, decoder_learned_pos=False, decoder_normalize_before=False, decoder_output_dim=1024, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', dropout=0.2, empty_cache_freq=0, encoder_attention_heads=16, encoder_embed_dim=1024, encoder_embed_path=None, encoder_ffn_embed_dim=8192, encoder_layerdrop=0, encoder_layers=6, encoder_layers_to_keep=None, encoder_learned_pos=False, encoder_normalize_before=False, eval_bleu=True, eval_bleu_args='{"beam": 5, "max_len_a": 1.2, "max_len_b": 10}', eval_bleu_detok='moses', eval_bleu_detok_args=None, eval_bleu_print_samples=True, eval_bleu_remove_bpe='@@ ', eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, fixed_validation_seed=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, label_smoothing=0.1, layernorm_embedding=False, left_pad_source='True', left_pad_target='False', load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr=[5e-05], lr_scheduler='inverse_sqrt', max_epoch=10, max_sentences=None, max_sentences_valid=None, max_source_positions=1024, max_target_positions=1024, max_tokens=4096, max_tokens_valid=4096, max_update=0, maximize_best_checkpoint_metric=True, memory_efficient_bf16=False, memory_efficient_fp16=False, min_loss_scale=0.0001, min_lr=-1, model_parallel_size=1, no_cross_attention=False, no_epoch_checkpoints=True, no_last_checkpoints=False, no_progress_bar=False, no_save=False, no_save_optimizer_state=False, no_scale_embedding=False, no_seed_provided=True, no_token_positional_embeddings=False, nprocs_per_node=1, num_batch_buckets=0, num_workers=1, optimizer='adam', optimizer_overrides='{}', patience=-1, profile=False, quant_noise_pq=0, quant_noise_pq_block_size=8, quant_noise_scalar=0, quantization_config_path=None, required_batch_size_multiple=8, reset_dataloader=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=True, restore_file='../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt', save_dir='../checkpoints/EMEA_p_4_r', save_interval=1, save_interval_updates=0, scoring='bleu', seed=1, sentence_avg=False, share_all_embeddings=False, share_decoder_input_output_embed=True, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, stop_time_hours=0, target_lang=None, task='translation', tensorboard_logdir='', threshold_loss_scale=None, tie_adaptive_weights=False, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, update_freq=[1], upsample_primary=1, use_bmuf=False, use_old_adam=False, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, warmup_init_lr=-1, warmup_updates=4000, weight_decay=0.0001)
2021-02-04 18:40:29 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-02-04 18:40:29 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-02-04 18:40:29 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase4_0.5_tag_rare_EMEA/valid.de-en.de
2021-02-04 18:40:29 | INFO | fairseq.data.data_utils | loaded 151 examples from: ../../../data-bin/phrase4_0.5_tag_rare_EMEA/valid.de-en.en
2021-02-04 18:40:29 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase4_0.5_tag_rare_EMEA valid de-en 151 examples
2021-02-04 18:40:33 | INFO | fairseq_cli.train | TransformerModel(
  (encoder): TransformerEncoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerEncoderLayer(
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (dropout_module): FairseqDropout()
        (activation_dropout_module): FairseqDropout()
        (fc1): Linear(in_features=1024, out_features=8192, bias=True)
        (fc2): Linear(in_features=8192, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
  )
  (decoder): TransformerDecoder(
    (dropout_module): FairseqDropout()
    (embed_tokens): Embedding(42024, 1024, padding_idx=1)
    (embed_positions): SinusoidalPositionalEmbedding()
    (layers): ModuleList(
      (0): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (1): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (2): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (3): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (4): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
      (5): TransformerDecoderLayer(
        (dropout_module): FairseqDropout()
        (self_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (activation_dropout_module): FairseqDropout()
        (self_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (encoder_attn): MultiheadAttention(
          (dropout_module): FairseqDropout()
          (k_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (v_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (q_proj): Linear(in_features=1024, out_features=1024, bias=True)
          (out_proj): Linear(in_features=1024, out_features=1024, bias=True)
        )
        (encoder_attn_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
        (fc1): Linear(in_features=1024, out_features=4096, bias=True)
        (fc2): Linear(in_features=4096, out_features=1024, bias=True)
        (final_layer_norm): LayerNorm((1024,), eps=1e-05, elementwise_affine=True)
      )
    )
    (output_projection): Linear(in_features=1024, out_features=42024, bias=False)
  )
)
2021-02-04 18:40:33 | INFO | fairseq_cli.train | model transformer_vaswani_wmt_en_de_big, criterion LabelSmoothedCrossEntropyCriterion
2021-02-04 18:40:33 | INFO | fairseq_cli.train | num. model params: 312778752 (num. trained: 312778752)
2021-02-04 18:40:37 | INFO | fairseq.trainer | detected shared parameter: decoder.embed_tokens.weight <- decoder.output_projection.weight
2021-02-04 18:40:37 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-04 18:40:37 | INFO | fairseq.utils | rank   0: capabilities =  7.0  ; total memory = 32.000 GB ; name = GRID V100D-32Q                          
2021-02-04 18:40:37 | INFO | fairseq.utils | ***********************CUDA enviroments for all 1 workers***********************
2021-02-04 18:40:37 | INFO | fairseq_cli.train | training on 1 devices (GPUs/TPUs)
2021-02-04 18:40:37 | INFO | fairseq_cli.train | max tokens per GPU = 4096 and max sentences per GPU = None
2021-02-04 18:40:38 | INFO | fairseq.trainer | loaded checkpoint ../../../models/wmt19.de-en.joined-dict.ensemble//model1.pt (epoch 16 @ 0 updates)
2021-02-04 18:40:38 | INFO | fairseq.trainer | loading train data for epoch 1
2021-02-04 18:40:38 | INFO | fairseq.data.data_utils | loaded 93981 examples from: ../../../data-bin/phrase4_0.5_tag_rare_EMEA/train.de-en.de
2021-02-04 18:40:38 | INFO | fairseq.data.data_utils | loaded 93981 examples from: ../../../data-bin/phrase4_0.5_tag_rare_EMEA/train.de-en.en
2021-02-04 18:40:38 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase4_0.5_tag_rare_EMEA train de-en 93981 examples
2021-02-04 18:40:39 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-04 18:40:39 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 64.0
2021-02-04 18:40:39 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 32.0
2021-02-04 18:40:39 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 16.0
2021-02-04 18:40:40 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 8.0
2021-02-04 18:40:40 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 4.0
2021-02-04 18:40:40 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 2.0
2021-02-04 18:40:40 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 1.0
2021-02-04 18:40:49 | INFO | fairseq.trainer | NOTE: overflow detected, setting loss scale to: 0.5
2021-02-04 18:40:59 | INFO | train_inner | epoch 001:    108 / 163 loss=4.673, nll_loss=3.087, ppl=8.5, wps=19099.5, ups=5.19, wpb=3681.2, bsz=586.1, num_updates=100, lr=1.25e-06, gnorm=38.465, loss_scale=1, train_wall=19, wall=23
2021-02-04 18:41:10 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:41:10 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:41:10 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:41:11 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast acting insulin and can be used together with long acting insulin preparations.
2021-02-04 18:41:11 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:41:12 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood sugar control may be associated with symptoms that are known as acute painful neuropathy and are usually reversible.
2021-02-04 18:41:12 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:41:15 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two studies with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (one study with 182 patients). In the studies, actrapid was compared to a human insulin analogue (insulin aspart) by measuring the concentration in the blood of a substance called glycosylated hemoglobin (HbA1c), which indicates how well the blood sugar is regulated. What benefit did actrapid show in these studies? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-04 18:41:15 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:41:15 | INFO | valid | epoch 001 | valid on 'valid' subset | loss 3.928 | nll_loss 2.223 | ppl 4.67 | bleu 31.49 | wps 726.9 | wpb 1083 | bsz 37.8 | num_updates 155
2021-02-04 18:41:15 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:41:32 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 1 @ 155 updates, score 31.49) (writing took 16.299400676973164 seconds)
2021-02-04 18:41:32 | INFO | fairseq_cli.train | end of epoch 1 (average epoch stats below)
2021-02-04 18:41:32 | INFO | train | epoch 001 | loss 4.313 | nll_loss 2.664 | ppl 6.34 | wps 10721.2 | ups 2.99 | wpb 3584.2 | bsz 568.7 | num_updates 155 | lr 1.9375e-06 | gnorm 27.641 | loss_scale 1 | train_wall 31 | wall 55
2021-02-04 18:41:32 | INFO | fairseq_cli.train | begin training epoch 1
2021-02-04 18:41:40 | INFO | train_inner | epoch 002:     45 / 163 loss=3.427, nll_loss=1.646, ppl=3.13, wps=8540.9, ups=2.44, wpb=3506.4, bsz=572.8, num_updates=200, lr=2.5e-06, gnorm=6.48, loss_scale=0, train_wall=19, wall=64
2021-02-04 18:42:00 | INFO | train_inner | epoch 002:    145 / 163 loss=3.117, nll_loss=1.342, ppl=2.53, wps=18867.1, ups=5.24, wpb=3601.2, bsz=569.6, num_updates=300, lr=3.75e-06, gnorm=3.441, loss_scale=0, train_wall=19, wall=83
2021-02-04 18:42:03 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:42:04 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:42:04 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:42:04 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast acting insulin and can be used together with long acting insulin preparations.
2021-02-04 18:42:04 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:42:05 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy A rapid improvement in blood glucose control may be associated with symptoms known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:42:05 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:42:09 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two studies with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (one study with 182 patients). In the studies, actrapid was compared to a human insulin analogue (insulin aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is regulated. What benefit has actrapid shown in these studies? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-04 18:42:09 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:42:09 | INFO | valid | epoch 002 | valid on 'valid' subset | loss 3.843 | nll_loss 2.136 | ppl 4.4 | bleu 33.55 | wps 725.7 | wpb 1083 | bsz 37.8 | num_updates 318 | best_bleu 33.55
2021-02-04 18:42:09 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:42:28 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 2 @ 318 updates, score 33.55) (writing took 19.578088290058076 seconds)
2021-02-04 18:42:28 | INFO | fairseq_cli.train | end of epoch 2 (average epoch stats below)
2021-02-04 18:42:28 | INFO | train | epoch 002 | loss 3.143 | nll_loss 1.362 | ppl 2.57 | wps 10395.1 | ups 2.89 | wpb 3593.7 | bsz 576.6 | num_updates 318 | lr 3.975e-06 | gnorm 3.741 | loss_scale 0 | train_wall 31 | wall 112
2021-02-04 18:42:28 | INFO | fairseq_cli.train | begin training epoch 2
2021-02-04 18:42:44 | INFO | train_inner | epoch 003:     82 / 163 loss=2.93, nll_loss=1.137, ppl=2.2, wps=8231.4, ups=2.26, wpb=3647.2, bsz=591.9, num_updates=400, lr=5e-06, gnorm=2.755, loss_scale=0, train_wall=19, wall=127
2021-02-04 18:42:59 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:43:00 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:43:00 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:43:01 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:43:01 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:43:02 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Occasional - peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:43:02 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:43:05 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared to a human insulin analogue (insulin Aspart) by measuring the concentration of a substance called glycosylated haemoglobin (HbA1c) in the blood that indicates how well the blood sugar is regulated. What benefit has actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6-month treatment with actrapid.
2021-02-04 18:43:05 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:43:05 | INFO | valid | epoch 003 | valid on 'valid' subset | loss 3.75 | nll_loss 2.021 | ppl 4.06 | bleu 36.25 | wps 725.5 | wpb 1083 | bsz 37.8 | num_updates 481 | best_bleu 36.25
2021-02-04 18:43:05 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:43:24 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 3 @ 481 updates, score 36.25) (writing took 19.208751800470054 seconds)
2021-02-04 18:43:24 | INFO | fairseq_cli.train | end of epoch 3 (average epoch stats below)
2021-02-04 18:43:24 | INFO | train | epoch 003 | loss 2.882 | nll_loss 1.084 | ppl 2.12 | wps 10469.1 | ups 2.91 | wpb 3593.7 | bsz 576.6 | num_updates 481 | lr 6.0125e-06 | gnorm 2.626 | loss_scale 0 | train_wall 31 | wall 168
2021-02-04 18:43:24 | INFO | fairseq_cli.train | begin training epoch 3
2021-02-04 18:43:28 | INFO | train_inner | epoch 004:     19 / 163 loss=2.848, nll_loss=1.046, ppl=2.07, wps=8011, ups=2.27, wpb=3523.2, bsz=550.2, num_updates=500, lr=6.25e-06, gnorm=2.45, loss_scale=0, train_wall=19, wall=171
2021-02-04 18:43:47 | INFO | train_inner | epoch 004:    119 / 163 loss=2.728, nll_loss=0.916, ppl=1.89, wps=18796.7, ups=5.23, wpb=3591.2, bsz=584.7, num_updates=600, lr=7.5e-06, gnorm=2.313, loss_scale=0, train_wall=19, wall=190
2021-02-04 18:43:55 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:43:56 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:43:56 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:43:57 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:43:57 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:43:58 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with conditions known as acute painful neuropathy, which are usually reversible.
2021-02-04 18:43:58 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:44:01 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1 954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared to a human insulin analogue (insulin Aspart) by measuring the concentration of a substance known as glycosylated haemoglobin (HbA1c) in the blood that indicates how well blood glucose is regulated. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6-month treatment with Actrapid.
2021-02-04 18:44:01 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:44:01 | INFO | valid | epoch 004 | valid on 'valid' subset | loss 3.682 | nll_loss 1.936 | ppl 3.83 | bleu 37.45 | wps 717.7 | wpb 1083 | bsz 37.8 | num_updates 644 | best_bleu 37.45
2021-02-04 18:44:01 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:44:18 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 4 @ 644 updates, score 37.45) (writing took 17.162438449449837 seconds)
2021-02-04 18:44:18 | INFO | fairseq_cli.train | end of epoch 4 (average epoch stats below)
2021-02-04 18:44:18 | INFO | train | epoch 004 | loss 2.737 | nll_loss 0.927 | ppl 1.9 | wps 10838.2 | ups 3.02 | wpb 3593.7 | bsz 576.6 | num_updates 644 | lr 8.05e-06 | gnorm 2.209 | loss_scale 0 | train_wall 31 | wall 222
2021-02-04 18:44:18 | INFO | fairseq_cli.train | begin training epoch 4
2021-02-04 18:44:29 | INFO | train_inner | epoch 005:     56 / 163 loss=2.659, nll_loss=0.841, ppl=1.79, wps=8574.1, ups=2.38, wpb=3599.1, bsz=584.1, num_updates=700, lr=8.75e-06, gnorm=1.983, loss_scale=0, train_wall=19, wall=232
2021-02-04 18:44:48 | INFO | train_inner | epoch 005:    156 / 163 loss=2.661, nll_loss=0.848, ppl=1.8, wps=18770.7, ups=5.24, wpb=3582.6, bsz=569.4, num_updates=800, lr=1e-05, gnorm=2.154, loss_scale=0, train_wall=19, wall=251
2021-02-04 18:44:49 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:44:50 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:44:50 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:44:51 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin preparations.
2021-02-04 18:44:51 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:44:52 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy, which is usually reversible.
2021-02-04 18:44:52 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:44:55 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well glucose is regulated. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-04 18:44:55 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:44:55 | INFO | valid | epoch 005 | valid on 'valid' subset | loss 3.655 | nll_loss 1.9 | ppl 3.73 | bleu 38.69 | wps 776 | wpb 1083 | bsz 37.8 | num_updates 807 | best_bleu 38.69
2021-02-04 18:44:55 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:45:13 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 5 @ 807 updates, score 38.69) (writing took 18.306558712385595 seconds)
2021-02-04 18:45:13 | INFO | fairseq_cli.train | end of epoch 5 (average epoch stats below)
2021-02-04 18:45:13 | INFO | train | epoch 005 | loss 2.636 | nll_loss 0.817 | ppl 1.76 | wps 10690 | ups 2.97 | wpb 3593.7 | bsz 576.6 | num_updates 807 | lr 1.00875e-05 | gnorm 2.035 | loss_scale 0 | train_wall 31 | wall 276
2021-02-04 18:45:13 | INFO | fairseq_cli.train | begin training epoch 5
2021-02-04 18:45:31 | INFO | train_inner | epoch 006:     93 / 163 loss=2.566, nll_loss=0.74, ppl=1.67, wps=8545.1, ups=2.34, wpb=3655.5, bsz=567.2, num_updates=900, lr=1.125e-05, gnorm=1.638, loss_scale=0, train_wall=19, wall=294
2021-02-04 18:45:44 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:45:45 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:45:45 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:45:45 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is a fast-acting insulin and can be used together with long-acting insulin products.
2021-02-04 18:45:45 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:45:46 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy and is usually reversible.
2021-02-04 18:45:46 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:45:49 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid has been studied in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is adjusted. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-04 18:45:49 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:45:49 | INFO | valid | epoch 006 | valid on 'valid' subset | loss 3.648 | nll_loss 1.894 | ppl 3.72 | bleu 40.74 | wps 914.2 | wpb 1083 | bsz 37.8 | num_updates 970 | best_bleu 40.74
2021-02-04 18:45:49 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:46:06 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 6 @ 970 updates, score 40.74) (writing took 17.55205479077995 seconds)
2021-02-04 18:46:06 | INFO | fairseq_cli.train | end of epoch 6 (average epoch stats below)
2021-02-04 18:46:06 | INFO | train | epoch 006 | loss 2.551 | nll_loss 0.726 | ppl 1.65 | wps 11009.3 | ups 3.06 | wpb 3593.7 | bsz 576.6 | num_updates 970 | lr 1.2125e-05 | gnorm 1.757 | loss_scale 0 | train_wall 31 | wall 330
2021-02-04 18:46:06 | INFO | fairseq_cli.train | begin training epoch 6
2021-02-04 18:46:12 | INFO | train_inner | epoch 007:     30 / 163 loss=2.529, nll_loss=0.703, ppl=1.63, wps=8479.5, ups=2.43, wpb=3493.9, bsz=580.2, num_updates=1000, lr=1.25e-05, gnorm=1.838, loss_scale=0, train_wall=19, wall=335
2021-02-04 18:46:31 | INFO | train_inner | epoch 007:    130 / 163 loss=2.477, nll_loss=0.646, ppl=1.56, wps=18955.5, ups=5.25, wpb=3608.7, bsz=585.1, num_updates=1100, lr=1.375e-05, gnorm=1.632, loss_scale=0, train_wall=19, wall=354
2021-02-04 18:46:37 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:46:38 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:46:38 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:46:39 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used in conjunction with long-acting insulin products.
2021-02-04 18:46:39 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:46:39 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy and is usually reversible.
2021-02-04 18:46:39 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:46:42 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is adjusted. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-04 18:46:42 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:46:42 | INFO | valid | epoch 007 | valid on 'valid' subset | loss 3.653 | nll_loss 1.899 | ppl 3.73 | bleu 41.17 | wps 962.6 | wpb 1083 | bsz 37.8 | num_updates 1133 | best_bleu 41.17
2021-02-04 18:46:42 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:46:59 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 7 @ 1133 updates, score 41.17) (writing took 17.430906873196363 seconds)
2021-02-04 18:46:59 | INFO | fairseq_cli.train | end of epoch 7 (average epoch stats below)
2021-02-04 18:46:59 | INFO | train | epoch 007 | loss 2.481 | nll_loss 0.65 | ppl 1.57 | wps 11064 | ups 3.08 | wpb 3593.7 | bsz 576.6 | num_updates 1133 | lr 1.41625e-05 | gnorm 1.576 | loss_scale 0 | train_wall 31 | wall 383
2021-02-04 18:46:59 | INFO | fairseq_cli.train | begin training epoch 7
2021-02-04 18:47:12 | INFO | train_inner | epoch 008:     67 / 163 loss=2.467, nll_loss=0.632, ppl=1.55, wps=8838.4, ups=2.45, wpb=3609.1, bsz=588, num_updates=1200, lr=1.5e-05, gnorm=1.688, loss_scale=0, train_wall=19, wall=395
2021-02-04 18:47:30 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:47:31 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:47:31 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:47:32 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin products.
2021-02-04 18:47:32 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:47:32 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy and is usually reversible.
2021-02-04 18:47:32 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:47:35 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). In the trials, Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance called glycosylated haemoglobin (HbA1c), which indicates how well the blood sugar is controlled. What benefit has Actrapid shown in these trials? Concentrations of HbA1c remained relatively stable during the 6 months of treatment with Actrapid.
2021-02-04 18:47:35 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:47:35 | INFO | valid | epoch 008 | valid on 'valid' subset | loss 3.667 | nll_loss 1.912 | ppl 3.76 | bleu 41.71 | wps 937.8 | wpb 1083 | bsz 37.8 | num_updates 1296 | best_bleu 41.71
2021-02-04 18:47:35 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:47:53 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 8 @ 1296 updates, score 41.71) (writing took 18.18028796557337 seconds)
2021-02-04 18:47:53 | INFO | fairseq_cli.train | end of epoch 8 (average epoch stats below)
2021-02-04 18:47:53 | INFO | train | epoch 008 | loss 2.424 | nll_loss 0.585 | ppl 1.5 | wps 10888 | ups 3.03 | wpb 3593.7 | bsz 576.6 | num_updates 1296 | lr 1.62e-05 | gnorm 1.555 | loss_scale 0 | train_wall 31 | wall 436
2021-02-04 18:47:53 | INFO | fairseq_cli.train | begin training epoch 8
2021-02-04 18:47:54 | INFO | train_inner | epoch 009:      4 / 163 loss=2.394, nll_loss=0.553, ppl=1.47, wps=8565.3, ups=2.38, wpb=3593.9, bsz=557.7, num_updates=1300, lr=1.625e-05, gnorm=1.337, loss_scale=0, train_wall=19, wall=437
2021-02-04 18:48:13 | INFO | train_inner | epoch 009:    104 / 163 loss=2.363, nll_loss=0.518, ppl=1.43, wps=19153.5, ups=5.26, wpb=3638.7, bsz=566.2, num_updates=1400, lr=1.75e-05, gnorm=1.273, loss_scale=0, train_wall=19, wall=456
2021-02-04 18:48:24 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:48:25 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide contains metacresol, which can cause allergic reactions.
2021-02-04 18:48:25 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:48:25 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin products.
2021-02-04 18:48:25 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:48:26 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy and is usually reversible.
2021-02-04 18:48:26 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:48:28 | INFO | fairseq.tasks.translation | example hypothesis: Actrapide was investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). Actrapide was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates how well blood sugar is controlled. What benefit has actrapide shown in these trials? HbA1c concentrations remained relatively stable during 6 months of treatment with actrapide.
2021-02-04 18:48:28 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:48:28 | INFO | valid | epoch 009 | valid on 'valid' subset | loss 3.715 | nll_loss 1.972 | ppl 3.92 | bleu 41.36 | wps 979.1 | wpb 1083 | bsz 37.8 | num_updates 1459 | best_bleu 41.71
2021-02-04 18:48:28 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:48:35 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_last.pt (epoch 9 @ 1459 updates, score 41.36) (writing took 6.247440003789961 seconds)
2021-02-04 18:48:35 | INFO | fairseq_cli.train | end of epoch 9 (average epoch stats below)
2021-02-04 18:48:35 | INFO | train | epoch 009 | loss 2.367 | nll_loss 0.522 | ppl 1.44 | wps 14026.6 | ups 3.9 | wpb 3593.7 | bsz 576.6 | num_updates 1459 | lr 1.82375e-05 | gnorm 1.364 | loss_scale 0 | train_wall 31 | wall 478
2021-02-04 18:48:35 | INFO | fairseq_cli.train | begin training epoch 9
2021-02-04 18:48:43 | INFO | train_inner | epoch 010:     41 / 163 loss=2.328, nll_loss=0.48, ppl=1.4, wps=12029.7, ups=3.35, wpb=3589.2, bsz=588, num_updates=1500, lr=1.875e-05, gnorm=1.314, loss_scale=0, train_wall=19, wall=486
2021-02-04 18:49:02 | INFO | train_inner | epoch 010:    141 / 163 loss=2.353, nll_loss=0.507, ppl=1.42, wps=18728.6, ups=5.27, wpb=3552, bsz=578.5, num_updates=1600, lr=2e-05, gnorm=1.479, loss_scale=0, train_wall=19, wall=505
2021-02-04 18:49:06 | INFO | fairseq_cli.train | begin validation on "valid" subset
2021-02-04 18:49:06 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid contains metacresol, which can cause allergic reactions.
2021-02-04 18:49:06 | INFO | fairseq.tasks.translation | example reference: Actrapid contains metacresol, which may cause allergic reactions.
2021-02-04 18:49:07 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid is fast-acting insulin and can be used together with long-acting insulin products.
2021-02-04 18:49:07 | INFO | fairseq.tasks.translation | example reference: Actrapid is a fast-acting insulin and may be used with long-acting insulins.
2021-02-04 18:49:08 | INFO | fairseq.tasks.translation | example hypothesis: Nervous system disorders Uncommon - Peripheral neuropathy Rapid improvement in blood glucose control may be associated with discomfort known as acute painful neuropathy and is usually reversible.
2021-02-04 18:49:08 | INFO | fairseq.tasks.translation | example reference: Nervous system disorders Uncommon - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
2021-02-04 18:49:10 | INFO | fairseq.tasks.translation | example hypothesis: Actrapid was investigated in patients with type 1 diabetes in which the pancreas is unable to produce insulin (two trials with 1,954 patients) and in patients with type 2 diabetes in which the body is unable to process insulin effectively (a trial with 182 patients). Actrapid was compared with a human insulin analogue (insulin Aspart) by measuring the concentration in the blood of a substance known as glycosylated haemoglobin (HbA1c), which indicates well controlled blood sugar. What benefit has Actrapid shown in these trials? HbA1c concentrations remained relatively stable during 6 months of treatment with Actrapid.
2021-02-04 18:49:10 | INFO | fairseq.tasks.translation | example reference: HbA1c levels remained fairly steady over the six months of treatment with Actrapid.
2021-02-04 18:49:10 | INFO | valid | epoch 010 | valid on 'valid' subset | loss 3.786 | nll_loss 2.05 | ppl 4.14 | bleu 42.82 | wps 915.7 | wpb 1083 | bsz 37.8 | num_updates 1622 | best_bleu 42.82
2021-02-04 18:49:10 | INFO | fairseq_cli.train | begin save checkpoint
2021-02-04 18:49:27 | INFO | fairseq.checkpoint_utils | saved checkpoint ../checkpoints/EMEA_p_4_r/checkpoint_best.pt (epoch 10 @ 1622 updates, score 42.82) (writing took 16.113404732197523 seconds)
2021-02-04 18:49:27 | INFO | fairseq_cli.train | end of epoch 10 (average epoch stats below)
2021-02-04 18:49:27 | INFO | train | epoch 010 | loss 2.323 | nll_loss 0.474 | ppl 1.39 | wps 11291.3 | ups 3.14 | wpb 3593.7 | bsz 576.6 | num_updates 1622 | lr 2.0275e-05 | gnorm 1.306 | loss_scale 0 | train_wall 31 | wall 530
2021-02-04 18:49:27 | INFO | fairseq_cli.train | done training in 527.8 seconds


###############################################################################
Peregrine Cluster
Job 17828785 for user 's3475743'
Finished at: Thu Feb  4 18:49:29 CET 2021

Job details:
============

Job ID              : 17828785
Name                : EMEA_p_4_r
User                : s3475743
Partition           : gpu
Nodes               : pg-gpu33
Number of Nodes     : 1
Cores               : 12
State               : COMPLETED
Submit              : 2021-02-04T17:32:21
Start               : 2021-02-04T18:40:26
End                 : 2021-02-04T18:49:29
Reserved walltime   : 23:55:00
Used walltime       : 00:09:03
Used CPU time       : 00:10:03 (efficiency:  9.26%)
% User (Computation): 59.23%
% System (I/O)      : 40.77%
Mem reserved        : 32G/node
Max Mem used        : 5.53G (pg-gpu33)
Max Disk Write      : 40.96K (pg-gpu33)
Max Disk Read       : 2.30M (pg-gpu33)
Average GPU usage   : 40.3% (pg-gpu33)


Acknowledgements:
=================

Please see this page for information about acknowledging Peregrine in your publications:

https://wiki.hpc.rug.nl/peregrine/introduction/scientific_output

################################################################################
